Information Provided By: 
Fly News Breaks for January 2, 2018
ELGX
Jan 2, 2018 | 06:21 EDT
JPMorgan analyst Michael Weinstein downgraded Endologix to Underweight and cut his price target for the shares to $5 from $6. The outlook for the company continued to "deteriorate" over the course of 2017 as pipeline and regulatory challenges mounted, Weinstein tells investors in a research note. He sees an "uncertain path to profitability" and a "very long" road to recovery for Endologix.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
